{"blog": [], "keywords": [{"value": "Banking and Financial Institutions", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Antitrust Laws and Competition Issues", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Regulation and Deregulation of Industry", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "ALLERGAN INC", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Halliburton Company", "name": "organizations", "rank": "7", "is_major": "N"}, {"value": "Baker Hughes Inc", "name": "organizations", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/pfizer-and-allergan-advisers-lose-out-on-200-million-in-fees.html", "document_type": "article", "byline": {"person": [{"lastname": "PICKER", "firstname": "Leslie", "role": "reported", "organization": "", "rank": 1}], "original": "By LESLIE PICKER"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/04/07/business/07db-fees/07db-fees-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/business/07db-fees/07db-fees-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg", "xlargeheight": "401", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 401}, {"url": "images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "468", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.", "pub_date": "2016-04-07T00:00:00Z", "news_desk": "Business", "headline": {"main": "Pfizer and Allergan Advisers Lose Out on $200 Million in Fees"}, "print_page": null, "snippet": "Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.", "_id": "5705573838f0d86865ca51b5", "slideshow_credits": null, "abstract": null}